Seller record · Telehealth service

Zeuss

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The weight loss pages and footer refer only to 503A and 503B state-licensed compounding pharmacy partners. 1 more criterion also fails; see the table below.

At a glance

ZeussTelehealth service

5/8criteria passed

Price: Compounded GLP-1 $125 a month, sold as a 60-day supply ($250); GIP/GLP-1 $199 a month
Sells: compounded GLP-1, compounded GIP/GLP-1, testosterone therapy, and 4 more
FDA letters: 1 on file

Visit Zeuss See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. 1 not verified, counting neither way. Recorded against Standard v1.1.

A telehealth service selling compounded GLP-1 and GIP/GLP-1 as one-time 60-day supplies with no subscription, beside testosterone therapy, enclomiphene, hormone therapy for women and skin and hair care. An FDA warning letter from February 2026 names the company.

Operating entity Zeuss LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Zeuss' body for him page; Zeuss' terms and conditions
S2	Prescription gating	NOT VERIFIED	Zeuss' body for him page; Zeuss' cancelation and return policy
S3	Pharmacy identification	FAIL	Zeuss' body for him page; Zeuss' terms and conditions
S4	Compounding disclosure	PASS	Zeuss' body for him page; Zeuss' body for her page
S5	Analytical documentation	FAIL	Zeuss' body for him page; Zeuss' terms and conditions
S6	Business address	PASS	Zeuss' contacts page
S7	Price disclosure	PASS	Zeuss' body for him page; Zeuss' body for her page; Zeuss' TRT for him page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed provider reviews each intake, confirms eligibility and writes the dosing plan, and the terms say the physicians are separate from the company and responsible for care.Source: Zeuss' body for him page; Zeuss' terms and conditions.

S2NOT VERIFIEDWhether payment is taken before the medical intake did not resolve, because the weight loss pages list the intake first and the provider's review second, while the cancellation policy says an order can be canceled for a full refund before a telehealth appointment is scheduled and applies its terms on completing a purchase. The check is open.Source: Zeuss' body for him page; Zeuss' cancelation and return policy.

S3FAILNo filling pharmacy is named. The weight loss pages and footer refer only to 503A and 503B state-licensed compounding pharmacy partners.Source: Zeuss' body for him page; Zeuss' terms and conditions.

S4PASSThe weight loss pages answer yes to whether the medications are compounded, and the footer on every page states that compounded medications have not been approved by the FDA.Source: Zeuss' body for him page; Zeuss' body for her page.

S5FAILNo certificate of analysis or lot document is published on the weight loss pages, in the terms or in the cancellation policy.Source: Zeuss' body for him page; Zeuss' terms and conditions.

S6PASSZeuss LLC at 1209 Orange Street, Corporate Trust Center, Wilmington, Delaware 19801, printed on the contact page.Source: Zeuss' contacts page.

S7PASSCompounded GLP-1 costs $125 a month, sold as a 60-day supply for $250, and compounded GIP/GLP-1 costs $199 a month, $398 for 60 days, with the provider review, medication and cold-chain shipping included and no subscription. Testosterone therapy starts at $99 a month and enclomiphene at $79 a month.Source: Zeuss' body for him page; Zeuss' body for her page; Zeuss' TRT for him page.

S8PASSFDA warning letter 717985, February 2026, names Zeuss LLC doing business as Zeuss, reviews this website and writes to the Wilmington street address and support address the seller prints. It says pictured labels named Zeuss as the compounder of tirzepatide products and that claims calling GLP-1 FDA approved and clinically proven present the compounded products as FDA-approved. No FDA action has halted the business, and the seller still trades.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded GLP-1, compounded GIP/GLP-1, testosterone therapy, enclomiphene, HCG, hormone therapy for women, skin and hair treatments.

Enforcement documents on file: 1 warning letter

FDA warning letter 717985, issued February 2026, to Zeuss LLC dba ZeussPictured labels identify Zeuss as the compounder of tirzepatide products when it is not, and claims that GLP-1 is FDA approved and clinically proven present the compounded products as FDA-approved.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit Zeuss

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.